Clinical update

New drug available for head and neck cancer patients not responding to chemotherapy

The National Institute for Health and Care Excellence recommends nivolumab is made available for head and neck cancer that has progressed following chemotherapy.

This article is for subscribers only

Latest print edition

Jobs